Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Fluicell ABOSTO:FLUI 47 EV-to-EBITDA is 13.70 as of Sep. 05, 2026. GuruFocus rates OSTO:FLUI with a GF Score™ of 47/100 and a GF Value™ of kr80.63 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 403 Biotechnology companies, Fluicell AB ranks better than 50.12% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Fluicell AB's enterprise value is kr44.97 Mil.
Fluicell AB's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was kr3.28 Mil. Therefore, Fluicell AB's EV-to-EBITDA for today is 13.70.
The historical rank and industry rank for Fluicell AB's EV-to-EBITDA or its related term are showing as below:
OSTO:FLUI'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -39.92 Med: -2.71 Max: 15.67
Current: 13.7
During the past 11 years, the highest EV-to-EBITDA of Fluicell AB was 15.67. The lowest was -39.92. And the median was -2.71.
OSTO:FLUI's EV-to-EBITDA is ranked better than 50.12% of 403
companies
in the Biotechnology industry
Industry Median: 13.7
vs OSTO:FLUI: 13.70
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Fluicell AB's PE Ratio (TTM) for today is calculated as:
Fluicell AB's share price for today is kr31.30.
Fluicell AB's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr2.040.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Fluicell AB's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OSTO:FLUI vs VRTX, REGN, MRNA: EV-to-EBITDA Comparison
For the Biotechnology subindustry, Fluicell AB's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Fluicell AB EV-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Fluicell AB's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Fluicell AB's EV-to-EBITDA falls into.
Fluicell AB's current Enterprise Value is kr44.97 Mil.
Fluicell AB's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr3.28 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Fluicell AB (OSTO:FLUI) has a EV-to-EBITDA of 13.70 as of Sep. 05, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Fluicell AB. According to the industry distribution chart, Fluicell AB ranks #201 out of 403 companies in the Biotechnology industry, placing it in the top 49.9%.
Is Fluicell AB's EV-to-EBITDA too high?
Fluicell AB's current EV-to-EBITDA is 13.70. The Biotechnology industry median EV-to-EBITDA is 13.70. Fluicell AB's value of 13.70 is 0% at this industry median. Based on the distribution chart, Fluicell AB ranks #201 out of 403 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Fluicell AB has a GF Score™ of 47/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Fluicell AB's EV-to-EBITDA compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Fluicell AB ranks #201 out of 403 companies for EV-to-EBITDA. This puts Fluicell AB in the upper half of its industry. The industry median EV-to-EBITDA is 13.70. Fluicell AB's value of 13.70 is 0% at this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Biotechnology company?
The median EV-to-EBITDA among Biotechnology companies is 13.70, based on 403 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Fluicell AB's current EV-to-EBITDA of 13.70 is 0% at the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Fluicell AB. For the Biotechnology industry, the median EV-to-EBITDA is 13.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Fluicell AB's current EV-to-EBITDA is 13.70. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Fluicell AB stock overvalued right now?
Based on GuruFocus' analysis, Fluicell AB (OSTO:FLUI) is currently considered Possible Value Trap. The stock's GF Value™ is kr80.63, compared to a current price of kr31.30 — trading 61.2% below its estimated fair value. The current EV-to-EBITDA is 13.70 and 0% at the Biotechnology industry median of 13.70. Fluicell AB's overall GF Score™ is 47/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Fluicell AB (OSTO:FLUI), the current EV-to-EBITDA is 13.70 as of Sep. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Fluicell AB (OSTO:FLUI) Overvalued in 2026?
Based on GuruFocus' analysis, Fluicell AB stock appears to be undervalued.
The current stock price of kr31.30 is trading 61.2% below its estimated GF Value™ of kr80.63.
GuruFocus considers Fluicell AB to be Possible Value Trap.
Key valuation signals for OSTO:FLUI:
EV-to-EBITDA: 13.70
GF Value™: kr80.63 vs. price of kr31.30 (61.2% below fair value)
Industry Position: 0% at the Biotechnology median (#201 of 403)
No single metric tells the full story. See the OSTO:FLUI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Fluicell AB is a Swedish life science company that conducts development in regenerative medicine and human tissue-based screening models for drug development, with a particular focus on the areas of type 1 diabetes, cardiac safety screening models, and kidney diseases. The company's platform for the production of human tissue that is based on Fluicell's technology for high-resolution 3D bioprinting, and which enables the creation of tissue-based products for use in drug development and regenerative medicine.
47GF Score
Get the complete analysis for OSTO:FLUI
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:FLUI has been successfully added to your 
